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Abstract
Context and Objective: The myokine irisin has been proposed to regulate energy homeostasis. Little is known about its
association with metabolic parameters and especially with parameters influencing pathways of lipid metabolism. In the
context of a clinical trial, an exploratory post hoc analysis has been performed in healthy subjects to determine whether
simvastatin and/or ezetimibe influence serum irisin levels. The direct effects of simvastatin on irisin were also examined in
primary human skeletal muscle cells (HSKMCs).
Design and Participants: A randomized, parallel 3-group study was performed in 72 men with mild hypercholesterolemia
and without apparent cardiovascular disease. Each group of 24 subjects received a 14-day treatment with either simvastatin
40 mg, ezetimibe 10 mg, or their combination.
Results: Baseline irisin concentrations were not significantly correlated with age, BMI, estimated GFR, thyroid parameters,
glucose, insulin, lipoproteins, non-cholesterol sterols, adipokines, inflammation markers and various molecular markers of
cholesterol metabolism. Circulating irisin increased significantly in simvastatin-treated but not in ezetimibe-treated subjects.
The changes were independent of changes in LDL-cholesterol and were not correlated with changes in creatine kinase
levels. In HSKMCs, simvastatin significantly increased irisin secretion as well as mRNA expression of its parent peptide
hormone FNDC5. Simvastatin significantly induced cellular reactive oxygen species levels along with expression of pro- and
anti-oxidative genes such as Nox2, and MnSOD and catalase, respectively. Markers of cellular stress such as atrogin-1 mRNA
and Bax protein expression were also induced by simvastatin. Decreased cell viability and increased irisin secretion by
simvastatin was reversed by antioxidant mito-TEMPO, implying in part that irisin is secreted as a result of increased
mitochondrial oxidative stress and subsequent myocyte damage.
Conclusions: Simvastatin increases irisin concentrations in vivo and in vitro. It remains to be determined whether this
increase is a result of muscle damage or a protective mechanism against simvastatin-induced cellular stress.
Trial Registration: ClinicalTrials.gov NCT00317993 http://clinicaltrials.gov/ct2/show/NCT00317993.
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Introduction
Irisin is a newly identified hormone secreted by myocytes (i.e., a
myokine) that has been proposed to mediate beneficial effects of
exercise and to influence multiple metabolic pathways, such as
energy and glucose metabolism [1–3]. Regulated by PPARc
coactivator-1alpha (PGC-1a), irisin is proteolytically processed
from the product of the fibronectin type-III domain containing
protein 5 (FNDC5) gene prior to being released into the
circulation. Irisin induces browning of subcutaneous adipocytes
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and thermogenesis by increasing uncoupling protein-1 (UCP1)
levels in both cell cultures and mouse models [3]. Considering the
metabolic benefits of ‘‘beige/brite (brown-in-white) fat’’ formation
[4,5], irisin administration has been proposed as a potential
therapeutic tool to treat obesity and diabetes [6] and thus may
have implications for decreasing cardiovascular risk.
A previous study from our group has suggested that age and
muscle mass are the primary predictors of circulating irisin
concentrations, with young male athletes having several-fold
higher levels than middle-aged obese women [7]. Furthermore,
irisin levels increased in response to acute exercise and decreased
after surgically induced weight loss in parallel to a decrease in body
mass [7]. Still, there is little knowledge regarding the way irisin
levels are regulated, for example by parameters involved in
lipoprotein metabolism pathways. Statins are widely used in the
treatment of hypercholesterolemia and for reducing cardiovascular
risk [8]. This becomes of particular interest given recent data
indicating that statin treatment and increased cardiovascular
fitness, which would be expected to elevate irisin levels, are both
associated with low mortality among dyslipidemic individuals [9].
The combination of statin treatment and increased fitness resulted
in substantially lower mortality risk than either alone, reinforcing
the importance of physical activity for individuals with dyslipide-
mia. Whether, similar to physical activity, statins may also increase
irisin levels and thus affect metabolism and improve risk among
dyslipidemic individuals through the irisin pathway too remains to
be explored.
The current clinical trial is to our knowledge the first study to
examine whether lipid-lowering drugs affect circulating irisin
levels. In this study we aimed to determine the effects of
simvastatin and ezetimibe on irisin by conducting a randomized
study in humans, and to characterize the parameters that predict
baseline irisin levels in this cohort in vivo.
To find the mechanisms related at the molecular level, we also
studied the effects of simvastatin on cellular stress markers as well
as on FNDC5/irisin expression and secretion in primary human
skeletal muscle cells (HSKMCs).
Subjects and Methods
Study design
The study design has been published before [10–14]. In short,
the present clinical trial was a single-center prospective, random-
ized, parallel 3-group open-label study (N = 24 subjects for each
group). The participants were randomized to receive simvastatin
(40 mg/day), ezetimibe (10 mg/day), or simvastatin (40 mg/day)
plus ezetimibe (10 mg/day) for a period of 2 weeks. Blood was
drawn in the morning after a 12-h fast at days 1 (before the
initiation of treatment) and 15 (at the end of the 2-week treatment
period). The original study has been registered at ClinicalTrials.-
gov NCT00317993.
Subjects
The study protocol of the clinical trial was approved by the
Ethics Committee of the University of Cologne, and all subjects
gave written informed consent. In the ex vivo study, each subject
had given written informed consent before taking part in the study
as approved by the Institutional Review Board at Beth Israel
Deaconess Medical Center. For the clinical trial, seventy-two male
volunteers were recruited by word of mouth and through
advertisements in the Cologne area and on campus. Inclusion
criteria were age between 18 and 60 years, body mass index (BMI)
between 18.5 and 30 kg/m2, LDL cholesterol concentrations
,190 mg/dl, triglycerides ,250 mg/dl and normal blood pres-
sure (,140/90 mmHg). Individuals who had received lipid-
lowering drugs within 12 weeks prior to study entry, those with
a history of excessive alcohol intake, liver disease, renal
dysfunction (estimated glomerular filtration rate ,60 ml/min),
rheumatologic disease, coronary heart disease, diabetes or other
endocrine disorders, eating disorders, history of recent substantial
(.10%) weight change, history of obesity (body mass index
.35 kg/m2) or taking medications known to affect lipoprotein
metabolism or the immune system were excluded from the study.
All patients were advised to keep their usual dietary habits and
their usual exercise levels throughout the trial.
Biochemical assays
Lipoproteins were analyzed on the day of blood collection in the
core laboratory of the Cologne University Medical Center. Irisin
was measured using a commercially available ELISA kit as
previously reported (sensitivity, 8.3 ng/ml; intra-assay coefficient
of variation, 4–6%) [7]. Creatine kinase was measured using an
automated analyzer (Hitachi cobas c311; Roche Diagnostics,
Indianapolis, IN). Insulin levels were measured by RIA (Diagnostic
System Laboratories, Webster, TX; sensitivity, 1.3 mU/ml; inter-
and intra-assay CVs, 4.7–12.2% and 4.5–8.3%, respectively).
Insulin resistance was estimated at baseline using the homeostasis
model assessment (HOMA) index_the product of fasting glucose
(mmol/l) and insulin (mU/ml) divided by the constant 22.5. Serum
high-sensitivity C-reactive protein was determined using the
Quantikine Human C-reactive protein immunoassay (R&D
Systems, Minneapolis, MN). Interleukin-6 was determined using
the human IL-6 Platinum ELISA (eBioscience Diagnostics, San
Diego, CA). Serum adiponectin, leptin, and resistin levels were
measured using radioimmunoassays (Linco Research, St. Charles,
MO, and BioVendor, Brno, Czech Republic), as previously
described [15–17], and high-molecular weight (HMW) adiponec-
tin was measured using an ELISA (ALPCO Diagnostics, Salem,
NH) as previously described [18]. The sensitivity of the
adiponectin assay was 1 ng/ml, intra-assay CV of 6.6%; resistin
0.2 ng/ml, CV 3.4–5.2%; leptin 0.5 ng/ml, CV 6–7%; and
HMW adiponectin 0.04 ng/ml and CV 2.8–8.4%. Coenzyme
Q10 was analyzed using HPLC as previously described [14].
Plasma concentrations of Lp-PLA2 were measured using ELISA
(USCN Life Science Inc., Wuhan, China). All other parameters
were measured using standard laboratory methods in the core
laboratory.
Primary human skeletal muscle cell culture
Abdominal/thigh muscle tissue was collected from patients
undergoing surgery [7]. Each subject had given written informed
consent before taking part in the study as approved by the
Institutional Review Board at Beth Israel Deaconess Medical
Center. Biopsied skeletal muscle tissue was immediately placed
into dissociation media containing 0.1% BSA, 0.25% trypsin-
EDTA, and 0.1% collagenase. Then the tissue was minced into
small pieces and was incubated in 37uC water bath for 1 hr. After
centrifugation, the pellet was resuspended in Skeletal Muscle Cell
Growth Media (PromoCell, Heidelberg, Germany) and plated on
T25 culture dish. After reaching 70–80% confluence, growth
media was switched to Skeletal Muscle Cell Differentiation Media
(PromoCell) for the differentiation of myoblasts into myotubes.
After 5 days of differentiation, the media was changed back to
growth media for additional 2–4 days for a stable differentiation,
according to the manufacturer’s instructions. A therapeutic dose of
40–80 mg/day simvastatin in vivo corresponds to approximately
5 mM simvastatin in vitro [19–21] and therefore, doses ranging
from 1 to 10 mM simvastatin were used in this study. For
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antioxidant experiments, 100 mM mito-TEMPO (Santa Cruz
Biotechnology, Dallas, TX) was administered 1 hr before
simvastatin treatment.
Gene expression analysis
Total RNA was extracted from HSKMCs using Trizol
(Invitrogen, Carlsbad, CA) according to a standard protocol.
mRNA levels of FNDC5, PGC-1a, atrogin-1, Nox2, Nox4,
MnSOD, and catalase were measured using TaqMan Gene
Expression Assays (Assay id: Hs00401006_m1, Hs01016719_m1,
Hs01041408_m1, Hs00166163_m1, Hs00418356_m1,
Hs00167309_m1, Hs00156308_m1, respectively). Briefly, Taq-
Man Gene Expression Assay primer mix and TaqMan PCR
Master Mix (Applied Biosystems, Foster City, CA) were added to
wells containing equal amounts of cDNA from HSKMCs. mRNA
expression was measured by real-time PCR using the comparative
CT method (ABI7500 FAST, Applied Biosystems). Data were
normalized to b-actin (id: Hs99999903_m1) in each reaction.
Irisin secretion in cell lysates and media
Cell lysates and the culture media were collected 24 and 48 hrs
after simvastatin treatment. After centrifugation to remove cell
debris, irisin was measured in cell lysates and culture media using a
commercially available kit as described above.
Morphological analysis
For morphological image analysis, the cells were photographed
using a light microscope (Carl Zeiss, Thornwood, NY). To
quantify the effect of simvastatin on myotube thinning, the
diameter of myotubes were measured as previously described [22].
Briefly, 4 random fields were selected to measure the muscle fiber
size using Image J software (Scion, Frederick, MD).
Measurement of oxidative stress
Differentiated HSKMCs were incubated with 2 and 10 mM
simvastatin for 48 hrs and then loaded with the peroxide-sensitive
fluorophore 29,79-dichlorofluorescein diacetate (DCF-DA; 5 mM;
Molecular Probes, Carlsbad, CA) for 20 min. Then, the fluores-
cent intensity was measured using a fluorimeter (BioTek,
Winooski, VT) at 485 nm excitation and 530 nm emission. The
fluorescence was measured in triplicate to avoid well-to-well
variation and was normalized by protein concentration.
Western blot analysis
After cells have been treated with 5 mM simvastatin for 24 and
48 hrs proteins were extracted with lysis buffer containing
20 mmol/l Tris-HCl (pH 7.4), 150 mmol/l NaCl, 5 mmol/l
EDTA, 0.1 mmol/l phenylmethylsulfonyl fluoride, 0.05% aproti-
nin, and 0.1% Igepal and then incubated for 30 min at 4uC. The
suspension was centrifuged for 15 min at 13,000 rpm, and the
supernatant was saved as the protein extract. After SDS-PAGE,
proteins were transferred to nitrocellulose membranes. The
membranes were blocked for 1 hr in Tris-buffered saline (TBS)
containing 5% nonfat dry milk and 0.1% Tween 20 and then
incubated with Bcl-2 and Bax antibody overnight (Santa Cruz
Biotechnology). Measurement of signal intensity was performed
using Image J processing and analysis software.
Cell viability assay
Cell viability was measured using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) assay kit (Sigma-
Aldrich, St. Louis, MO), according to the manufacturer’s
instructions.
Data analysis
Statistical analyses were performed using Stata11 (StataCorp
LP, College Station, TX). Descriptive statistics are presented as
counts (percentage proportions) or means 6 SD. The main
outcome parameters in the first part of the clinical trial were
Pearson’s or Spearman’s rank correlation coefficients (as appro-
priate) to estimate associations between baseline values of irisin
and other baseline parameters. Stepwise linear regression analyses
(bidirectional elimination procedure) were also performed to
identify parameters for model building. The main outcome
parameter in the second part of the clinical trial was percent
change in irisin concentrations from baseline after 2 weeks
treatment with lipid-lowering drugs. We used Student’s paired t-
test for statistical comparisons within the groups. All tests were
performed two-sided. P-values are presented descriptively.
HSKMC data are presented as means 6 SEM. Mean values
obtained from each group were compared using ANOVA with
subsequent Fisher’s significant difference method.
Results
Cross-sectional clinical trial: Correlation of irisin with
baseline parameters
The baseline subject characteristics are shown in Table 1. The
mean age of the subjects was 31.569.2 yrs (range 20–60 yrs),
mean body weight 85612 kg (range 64–115 kg), and mean BMI
was 25.763.2 kg/m2 (range 19.5–32.8 kg/m2). The baseline
subject characteristics were not different between the groups.
Circulating irisin concentrations were measured in 70 out of the 72
subjects (due to missing samples in 2) and had a mean value of
2656102 ng/ml, ranging from 85–518 ng/ml (Figure 1A).
We performed bivariate regression analysis of irisin concentra-
tions and the demographic, anthropometric, hormonal, and
metabolic parameters in order to identify parameters that may
influence irisin baseline concentrations (Table 1). The parameters
that were found to be significantly correlated with irisin were
lipoprotein(a) (R = –0.27), coenzyme Q10 (R = –0.22), and the
mRNA levels of LDL receptor (R = –0.40) and NPC1L1 (R =
–0.29).
None of the other parameters was significantly correlated with
irisin. However, there were weak negative correlations with age,
BMI, lean body mass, all lipoprotein fractions, and inflammation
markers (hsCRP, IL-6, Lp-PLA2 and blood neutrophil count).
There were no relevant correlations with smoking status, kidney or
thyroid function parameters, non-cholesterol sterols, and adipo-
kines (resistin, adiponectin, and leptin).
Stepwise linear regression analysis identified only 2 parameters
to have a significant correlation with irisin concentrations, namely
total cholesterol (beta coefficient –0.79, SE 0.37, F-to-remove 4.6)
and lipoprotein(a) (beta coefficient –2.68, SE 0.82, F-to-remove
10.7). The model had an adjusted R squared of 0.24, F = 8.5,
P = 0.0007.
Interventional clinical trial: Effect of lipid-lowering drugs
on irisin levels
The effects of the lipid-lowering drugs on lipoprotein concen-
trations were of expected magnitude and were reported before in
detail [12]. In short, ezetimibe decreased the main outcome
parameter low-density lipoprotein (LDL) cholesterol by 22610%,
simvastatin by 41612%, and the combination of the two drugs by
60610% (all P,0.001; Figure 1B). The changes of circulating
irisin in the three treatment groups were +3.8622.7% (P = 0.44),
+15.8632.5% (P = 0.05), and +11.7625.3% (P = 0.1), respective-
ly. When combining the two groups that received simvastatin
Effect of Simvastatin on Irisin in Humans
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(N = 48), the mean percent change of irisin was +13.8628.9%
(P = 0.01) with a mean increase from baseline of +28 ng/ml (95%
CI +7 to +49 ng/ml). The mean difference in the ezetimibe group,
however, was only +10 ng/ml (95% CI –17 to +38 ng/ml).
Figure 1C shows the individual irisin data in the three groups and
in the combined simvastatin group. There was no correlation
between changes in irisin concentrations and changes in LDL
cholesterol concentrations. However, there was a highly significant
intra-subject correlation between pre- and post-treatment irisin
concentrations (R = 0.82, P,0.0001). There was no correlation
between the change in irisin levels by simvastatin treatment and
the respective changes in lipoprotein(a), coenzyme Q10, and
mRNA levels of LDL receptor and NPC1L1 (Niemann-Pick C1-
like protein 1).
Since simvastatin has been known to induce muscle damage, we
measured creatine kinase levels and their correlation with
circulating irisin. As shown in Figure 2A and 2B, serum creatine
kinase levels were not different before and after simvastatin
treatment (P = 0.54), and changes in creatine kinase levels did not
correlate with changes in irisin levels in these patients (R = 0.0123).
This suggests that the increase in irisin levels in the simvastatin-
treated group was not due to considerable muscle damage.
In vitro studies
Effects of simvastatin on FNDC5/irisin expression and
secretion in primary HSKMCs. To assess the effect of
simvastatin on irisin more directly, we used primary HSKMCs
isolated from human muscle biopsies. Measurement of irisin in
media after 5 mM simvastatin treatment resulted in significantly
increased secretion of irisin compared to control after 48 hrs
(Figure 3A). Interestingly, irisin levels were also increased in the
HSKMC lysates of simvastatin-treated cells (Figure 3B). As shown
in Figure 3C and 3D, FNDC5 mRNA levels were upregulated
24 hrs after 5 mM simvastatin treatment. mRNA levels of PGC-
1a, a known upstream regulator of FNDC5 [3], and atrogin-1, a
known marker of muscle atrophy development [23,24], were also
significantly upregulated 24 hrs after 5 mM simvastatin treatment
(Figure 3E and 3F).
Effects of simvastatin on oxidative stress and cell viability
in primary HSKMCs. As shown in Figure 4A, 48 and 96 hrs of
5 mM simvastatin induced fiber thinning in HSKMCs with
significantly reduced myotube diameter (Figure 4B). The change
in morphology was correlated with increased intracellular
oxidative stress (Figure 4C) and induction by 2 mM and 10 mM
simvastatin of genes regulating reactive oxygen species such as
Nox2, MnSOD, and catalase whereas Nox4 remained unaltered
(Figures 4D–4G). Simvastatin treatment (5 mM) for 48 hrs also
significantly increased anti-apoptotic Bcl-2 and pro-apoptotic Bax
protein expression (Figure 4H and 4I) and subsequently reduced
cell viability by 20% (Figure 4J).
Effects of mitochondrial antioxidant on simvastatin-
induced changes in primary HSKMCs. To find a link
between simvastatin-induced oxidative stress and irisin in
HSKMCs, mitochondria-targeted antioxidant mito-TEMPO was
used. As shown in Figure 4J, reduction in cell viability induced by
48 hrs of simvastatin treatment was reversed by mito-TEMPO
pretreatment. Moreover, mito-TEMPO treatment was sufficient
Figure 1. Irisin and LDL cholesterol concentrations at baseline and after 2 weeks of treatment. (A) Frequency histogram and normal
distribution of irisin baseline concentrations. Data of N= 70 subjects were available. Mean 6 SD baseline concentrations were 2656102 ng/ml (range
85 to 518 ng/ml). (B) Percent change from baseline concentrations in LDL cholesterol (left) and irisin (right). (C) Individual changes from baseline to 2-
weeks irisin concentrations in the 3 treatment groups. The graph on the right shows the combined data of the subjects receiving simvastatin (either
alone or in combination with ezetimibe).
doi:10.1371/journal.pone.0072858.g001
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Table 1. Baseline characteristics of the randomized patients and correlation analyses between baseline values and baseline irisin
plasma concentrations.*
Parameter Baseline values
Correlation
coefficient** P value
Demographic characteristics
Age (years) 31.569.2 –0.14 0.26
Smoking status (N and %)
Current smokers 21 (29%)
Former smokers 9 (13%) 0.231
Never smokers 42 (58%)
Anthropometric characteristics, body composition and clinical parameters
Height (cm) 18167 –0.03 0.78
Weight (kg) 85612 –0.14 0.25
Body mass index (kg/m2) 25.763.2 –0.14 0.26
BIA body fat (%) 21.465.7 –0.03 0.82
BIA lean body mass (%) 66.066.4 –0.18 0.14
BIA ratio ECM/BCM 0.8260.09 0.07 0.58
Creatinine (mg/dl) 0.9660.12 0.06 0.62
Estimated glomerular filtration rate (ml/min) 135625 –0.01 0.94
Hormonal parameters
Thyroid stimulating hormone (mU/l) 1.6560.82 –0.10 0.42
Free triiodothyronine (ng/l) 3.760.4 –0.005 0.97
Free thyroxine (ng/l) 13.761.7 0.10 0.40
Glucose and lipid metabolism
Fasting blood glucose (mg/dl) 8868 0.03 0.84
Fasting insulin (mU/l) 9.968.4 0.12 0.32
HOMA index 2.261.8 0.19 0.13
Lipid metabolism parameters
Total cholesterol (mg/dl) 189635 –0.18 0.14
LDL cholesterol (mg/dl) 111630 –0.11 0.37
Non-HDL cholesterol (mg/dl) 126633 –0.12 0.32
HDL cholesterol (mg/dl) 64615 –0.16 0.20
Triglycerides (mg/dl) 95643 –0.11 0.38
Lipoprotein(a) (mg(dl) 16624 –0.27 0.02
Non-cholesterol sterols
Campesterol" 208683 0.04 0.72
Lathosterol" 138640 –0.05 0.69
Ratio campesterol/lathosterol (mg/mg) 1.861.3 –0.01 0.97
Adipokines/myokines
Resistin (ng/ml) 14.165.3 0.04 0.77
Adiponectin (mg/ml) 13.465.3 0.10 0.43
High molecular weight adiponectin (mg/ml) 2.762.0 0.13 0.28
Leptin (mg/ml) 3.062.8 0.02 0.85
Irisin (ng/ml) 2656102 1.00
Inflammation markers
High-sensitivity C-reactive protein (mg/l) 0.7560.93 –0.12 0.34
Interleukin-6 (ng/l) 0.9461.26 –0.19 0.12
Lipoprotein-associated phospholipase A2 (ng/ml) 1416194 –0.09 0.48
Blood neutrophil count (103/ml) 2.861.0 –0.10 0.40
Molecular markers of cholesterol metabolism
LDL receptor protein (PBMC){ 17.669.3 0.01 0.93
HMG-CoA reductase mRNA` 3.361.3 –0.15 0.21
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to block the irisin secretion induced by simvastatin (Figure 4K),
implying that irisin may be induced by simvastatin through an
oxidative stress-mediated mechanism in HSKMCs.
Discussion
This is the first prospective clinical trial investigating effects of
lipid-lowering agents on irisin concentrations in humans and the
first molecular study on the effect of simvastatin on irisin in human
myocytes. The main finding of our study is that circulating irisin is
increased in simvastatin-, but not in ezetimibe-, treated subjects
independently of its lipid-lowering effect. In addition, this increase
was neither correlated with creatine kinase levels nor with any
clinical symptoms of myopathy. Our results from experiments in
primary human muscle cells showed that simvastatin directly
upregulated PGC-1a and FNDC5 expression and increased irisin
secretion in vitro, partly through simvastatin-induced oxidative
stress.
The fact that circulating irisin was increased by simvastatin and
not by ezetimibe, a selective cholesterol absorption inhibitor
[25,26], could be interpreted as suggesting that the increase in
irisin secretion may be related to muscle damage [27]. Simvastatin
has been reported to upregulate PGC-1a and to decrease
oxidative stress and apoptosis in cardiac muscle [28]. However,
this upregulation is not observed in skeletal muscle from subjects
with statin-induced myopathy [28]. Although the therapeutic
effects of statins for managing cholesterol levels are well
established, some statins (particularly lipophilic statins) are known
to induce myopathy or rhabdomyolysis by mechanisms not yet
fully understood. Though muscle weakness and pain are clinically
much more frequent than rhabdomyolysis, it is hard to quantitate
the frequency of these symptoms, since markers of muscle damage
such as increased creatine kinase levels are often absent in these
patients [29,30]. We found no correlation between irisin and
creatine kinase levels, a currently accepted marker of muscle
damage, indicating either that the increase in irisin is not related to
muscle damage or that irisin is a marker of damage much more
sensitive than creatine kinase. Of note, we report a borderline
significant negative correlation between baseline coenzyme Q10
Figure 2. Increased irisin does not correlate with circulating creatine kinase levels. (A) Serum creatine kinase levels before and 2 weeks
after simvastatin treatment. (B) Correlation between change in irisin levels and change in creatine kinase levels in simvastatin-treated subjects. Values
are means 6 SEM of N= 23 subjects.
doi:10.1371/journal.pone.0072858.g002
Table 1. Cont.
Parameter Baseline values
Correlation
coefficient** P value
LDL receptor mRNA` 0.5260.32 –0.40 0.004
NPC1L1 mRNA` 33631 –0.29 0.02
PCSK9 mRNA` 1.760.1 –0.02 0.87
PCSK9 (ng/ml) 52620 0.01 0.94
Coenzyme Q10 (mg/ml) 0.9960.3 –0.22 0.06
*Continuous variables are expressed as means 6 SD (for smoking status N and percentage of total) of N= 72 patients.
**Pearson’s or Spearman’s rank correlation coefficient, where appropriate.
1Analysis of variance.
"The data indicate the ratio of the respective non-cholesterol sterol to cholesterol (mg/mg)6100.
{LDL receptor protein is given as flow cytometry-specific fluorescence, calculated by subtracting the nonspecific fluorescence intensity from the total fluorescence
intensity.
`Gene expression is given as number of the respective mRNA copies divided by the number of copies of the TATA housekeeping gene mRNA.
BIA, bioelectrical impedance analysis.
HOMA, homeostasis model assessment.
doi:10.1371/journal.pone.0072858.t001
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levels and baseline irisin (R = –0.22, P = 0.06). Statin therapy has
been associated with decreased Q10 levels and it has been
suggested that low Q10 levels may promote statin-associated
myopathies as a result of mitochondrial damage [14]. Whether the
increase in irisin is a specific response to simvastatin treatment, as
indicated by our in vitro data, or the unspecific result of muscular
cell damage or other, unknown mechanisms, remains to be
confirmed by future studies.
In contrast to the in vivo data, our in vitro data showed that
simvastatin, in a dose corresponding to the therapeutic dose in vivo,
significantly increased atrogin-1 mRNA expression, cellular
reactive oxygen species levels, and markers of apoptosis, and
there was a parallel induction of FNDC5 mRNA and irisin
secretion in HSKMCs. Galtier et al. have reported that in healthy
volunteers who received a high dose of simvastatin (80 mg/d),
subjects with the highest creatine kinase increase displayed
alterations in mitochondrial respiration and muscle calcium
homeostasis, as reflected by a significantly lower Vmax rotenone
succinate and an increase in Ca2+ spark amplitude, respectively
[31]. Also, several studies have shown that simvastatin-induced
mitochondrial dysfunction leads to increased oxidative stress
resulting in induction of PGC-1a, which is an important regulator
of mitochondrial biogenesis and metabolism [28]. Moreover, it has
been recently shown that simvastatin attenuates increases in
cardiorespiratory fitness and skeletal muscle mitochondrial content
(citrate synthase enzyme activity) when combined with exercise
training in overweight or obese patients at risk of the metabolic
syndrome [32].
In line with these previous reports, genes related to mitochon-
drial oxidative stress regulation were elevated in our study,
including MnSOD, by simvastatin treatment. Along with elevated
oxidative stress, pro-apoptotic Bax protein expression was
increased by simvastatin, with subsequent reduction in cell
viability. Expression of anti-apoptotic protein Bcl-2 was also
increased, suggesting a protective role against simvastatin-induced
cellular damage, similar to previous observations [19]. Important-
ly, mitochondria-targeted antioxidant mito-TEMPO treatment
was able to reverse the reduced cell viability as well as increased
irisin secretion by simvastatin in HSKMCs, implying that irisin
secretion by simvastatin could be related to oxidative stress. To
date, PGC-1a is the only known inducer of FNDC5 and indeed
our data show that simvastatin treatment induced both PGC-1a
and FNDC5 expression in HSKMCs. Interestingly, irisin levels
were increased not only in the media but also in cell lysates by
simvastatin. This may either be a result of increased synthesis
through observed induction of FNDC5 transcription or an
indication of increased storage of this protein, which has yet to
be elucidated. Moreover, whether the increase in irisin/FNDC5
Figure 3. Simvastatin increases irisin secretion and FNDC5 mRNA expression in human skeletal muscle cells (HSKMCs). Measurement
of irisin in media (A) and lysate (B) at 24 and 48 hrs after 5 mM simvastatin treatment. FNDC5 mRNA levels were measured by real-time PCR after 5 mM
simvastatin treatment for 6 and 24 hrs (C) or 1 and 5 mM for 24 hrs (D). mRNA levels of PGC-1a (E) and atrogin-1 (F) were also measured in
simvastatin-treated HSKMCs (5 mM, 6 and 24 hrs). Values are means 6 SEM of 4 individual experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0072858.g003
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mediates a ‘‘mitohormesis’’ mechanism downstream of PGC-1a or
is simply a result of cellular damage remains to be investigated.
Statins exert beneficial effects in both primary and secondary
cardiovascular disease prevention based on their potent choles-
terol-lowering effects [33]. However, the overall benefits observed
appear to occur much earlier and seem to be greater than what
might be expected from changes in lipid levels, suggesting effects
beyond cholesterol lowering alone. Various of such ‘‘pleiotropic
effects’’ of statins have been implicated in their antiatherosclerotic
effects [34]. Regarding the proposed beneficial effect of irisin on
‘browning’ of subcutaneous white adipose tissue and whole body
metabolism [35], it could be postulated that an increase in irisin by
statins could be beneficial, for example by influencing adipose
tissue metabolism and insulin resistance. Although it has been
suggested that statins may decrease body weight in individuals
with type 2 diabetes [36], which would be in line with irisin-
mediated weight reducing effects [7], no significant reports on
weight change have been reported in the majority of statin trials
[37]. Of note, the long-term diabetogenic effects of statins may be
mediated via the mitochondrial damage they induce since the
latter has been associated with insulin resistance [38]. In this
context, considering that irisin has been found to be low in patients
with type 2 diabetes [39], the statin-associated increase in irisin
concentrations may indeed represent a protective compensatory
reaction of the muscle cell.
The present study investigated cross-sectionally a wide variety of
parameters that may predict baseline irisin concentrations in
healthy men. The results of our previous study [7] suggested that
there are positive correlations of irisin with muscle mass, BMI,
glucose, ghrelin, and IGF-1 and negative correlations with age,
insulin, cholesterol and adiponectin levels. Recently, Moreno-
Navarrete et al. found an association between FNDC5 expression
in muscle and BMI in obese subjects [40]. However, here we
found no significant correlations of circulating irisin levels with the
majority of the parameters studied. This may be due to the
different study sample characteristics (women vs. men, obese vs.
lean, older vs. younger) or may be attributed to a smaller number
of subjects, the clinical characteristics of whom showed limited
Figure 4. Simvastatin induces muscle damage, oxidative stress, and apoptosis in human skeletal muscle cells, and mito-TEMPO
reverses simvastatin-induced cellular damage and irisin secretion. (A) Differentiated HSKMCs were incubated with 5 mM simvastatin for 48
and 96 hrs and representative pictures were taken. Enlarged inset pictures are shown for better viewing. (B) The myotube diameter was measured in
the images shown in (A) using Image J, as described in the methods. (C) Intracellular oxidative stress levels were measured with DCF-DA 48 hrs after 2
and 10 mM simvastatin treatment. (D–G) Expression of oxidative stress related genes, including Nox2, Nox4, MnSOD, and catalase were measured
24 hrs after 5 mM simvastatin treatment. (H–I) Protein levels of Bcl-2 and Bax after 24 and 48 hrs 5 mM simvastatin treatment and its quantification in
HSKMCs. (J) Cell viability was measured by MTT assay after 5 mM simvastatin treatment for 48 hrs. (K) Irisin secretion in media was measured 48 hrs
after 5 mM simvastatin treatment. For (J) and (K), 100 mM Mito-TEMPO was administered for 1 hr prior to simvastatin treatment. Values are means 6
SEM of 4 individual experiments. RFU: relative fluorescence unit, Statin: simvastatin, TEMPO: mito-TEMPO. *P,0.05 vs. control, **P,0.05 vs.48 hr
treated (B) or 2 mM simvastatin-treated (C) HSKMCs, {P,0.05 vs. simvastatin-treated HSKMCs.
doi:10.1371/journal.pone.0072858.g004
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variation in the present study. This may have reduced the capacity
to demonstrate significant associations. Nevertheless, one of the
strongest (negative) correlations was the one with NPC1L1
expression. NPC1L1 is critical for the uptake of cholesterol across
plasma membrane of the intestinal enterocyte, and is the direct
target of ezetimibe [41]. Recently, it has been shown that NPC1L1
has a surprising number of new functions, beyond mediating
cholesterol transport in the small intestine [42]. In specific,
NPC1L1 seems to be involved in energy homeostasis, as Labonte
et al. recently showed that NPC1L1 knock-out mice are resistant to
diet-induced obesity and hyperglycemia [43]. Moreover, we found
a negative correlation between irisin and LDLR expression. It has
been recently shown that LDLR-related protein 6 (LRP6), a
member of the LDLR family, regulates body fat and glucose
homeostasis by modulating PGC-1a expression [44]. PGC-1a is
also known to downregulate LDLR [45] and stimulate SREBP2-
mediated transactivation of human NPC1L1 [46]. Collectively,
the close relationship between NPC1L1, LDLR and irisin in our
study suggests that irisin may play a role in cholesterol homeostasis
or vice versa.
Recently, it has been shown that long-term statin treatment is
associated with the development of type 2 diabetes through
unknown mechanisms [47,48]. Given the improvement in obesity
and glucose homeostasis in FNDC5 overexpressed mice [7] and
the inverse association between irisin concentrations and prevalent
type 2 diabetes [49], increased irisin levels by statin treatment (as
observed in our study) may simply reflect a compensatory
mechanism activated to limit other, deleterious effects of statins.
We have previously reported that circulating irisin levels are
positively correlated with glucose and negatively correlated with
age, insulin, cholesterol, and adiponectin levels, indicating a
feedback loop of irisin in response to deterioration of insulin
sensitivity and glucose/lipid metabolism [7].
Strengths of our study are its novelty in terms of studying a new
metabolically important hormone, its randomized design and
robust statistical methodology, the blinded measurements of all
end-point parameters, the excellent treatment adherence (99%, as
determined by pill count) and the use of a ‘‘drug-naı¨ve’’
population, devoid of co-medications or co-morbidities which
could potentially alter the results. Limitation of our study includes
the short treatment period which could not have been sufficient to
detect the full extent of the statin effects on irisin. No a priori power
calculations were made for changes in irisin since the primary
outcome parameter of the study in the parent trial was change in
LDL cholesterol. In univariate analyses some statistically signifi-
cant correlations were found but alpha inflation cannot be
excluded as the reason driving these associations. Especially
stepwise linear regression procedures have been criticized to be
prone for generating chance findings due to multiple testing.
Therefore we abstained from further multivariate analysis model
building. Lastly, the clinical relevance of our findings remains to
be established.
Considering that irisin administration has been proposed as a
potential therapeutic tool to treat obesity and diabetes [50] and
thus may have implications for decreasing cardiovascular risk, our
results are of potential clinical relevance.
In conclusion, our results show that simvastatin increases
circulating irisin concentrations in vivo after two weeks of
treatment in healthy individuals and also in HSKMCs in vitro.
In HSKMCs, simvastatin-induced cellular stress markers as well
as protective response markers, and inhibition of mitochondrial
oxidative stress blocked simvastatin-induced irisin secretion,
suggesting a role of oxidative stress in irisin regulation in human
muscle. Whether the increase in irisin levels is a specific and
metabolically important effect or whether it is related unspeci-
fically to myocyte damage and/or cellular stress needs to be
investigated further. If irisin eventually proves to be related to
muscle damage, it might be speculated that irisin as circulating
biomarker of muscle damage is much more sensitive than
currently available markers. The results presented herein are
suggestive of interconnections between the irisin and lipid
metabolism pathways and warrant further study.
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